Plf 12adlx breplacement

The Medicines and Healthcare products Regulatory Agency regulates medicines, medical devices and blood components for transfusion in the UK.

To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).

The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 23 October 2024, approved a licence for the medicine donanemab (Kisunla) for use in the early stages of Alzheimer’s disease, following a thorough review of the benefits and risks.

We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved eplontersen (Wainzua) to treat adults with polyneuropathy associated with hereditary transthyretin amyloidosis (ATTRv), which is a rare progressive condition that runs in families caused by a protein called transthyretin (TTR).

Plf 12adlx bprice

The UK will be the first country in the world to introduce a tailored framework for the regulation of innovative products manufactured at or close to the location where a patient receives care.

The Medicines and Healthcare products Regulatory Agency (MHRA) is reminding healthcare professionals to ensure patients are aware of the known side effects of glucagon-like peptide-1 (GLP-1) receptor agonists.

The new legislation will introduce clearer and risk-proportionate requirements that improve the safety of medical devices across Great Britain and provide certainty for manufacturers ahead of introducing the wider future regulatory regime.

Plf 12adlx bmanual

Medicines and Healthcare products Regulatory Agency (MHRA) is highlighting our work training multiple World Health Organisation (WHO) polio laboratories around the world.